Filter by:RZ358RZ402Show AllRZ358 PublicationsPhase 2b RIZE Data Presentation by Hüseyin Demirbilek, M.D. at ESPE 2022Learn MoreContinuous Glucose Monitoring (CGM) Reveals Undertreated Hypoglycemia in Patients with Congenital HyperinsulinismLearn MoreSingle Dose Studies of RZ358 in Patients with Congenital Hyperinsulinism: Results of Population PK/PD Modeling and Simulation in Adult and Pediatric PatientsLearn MoreRezolute profiled in Nature’s BioPharma Dealmakers, Nature Biotechnology, and Nature Reviews Drug Discovery, November 2019 editionsLearn MoreAttenuation of Insulin Action by an Allosteric Insulin Receptor Antibody in Healthy Volunteers The Journal of Clinical Endocrinology & Metabolism, August 2017, 102(8):3021–3028 Learn MoreXOMA 358, a Novel Treatment for Hyperinsulinemic Hypoglycemia: Safety and Clinical Pharmacology from the First in Human Trial ENDO 2015 Annual Meeting Learn MoreInhibition of insulin receptor function by a human, allosteric monoclonal antibody: A potential new approach for the treatment of hyperinsulinemic hypoglycemia mAbs 6:1, 262–272; January/February 2014; © 2014 Landes Bioscience Learn More RZ402 PublicationsPlasma Kallikrein Mediates Angiotensin II Type 1 Receptor–Stimulated Retinal Vascular PermeabilityLearn MoreNonclinical safety and pharmacology of RZ402, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema as a daily oral therapyLearn MorePlasma Kallikrein Mediates Retinal Vascular Dysfunction and Induces Retinal Thickening in Diabetic Rats Diabetes, 60:1590–1598, May 2011 Learn More